[
  {
    "ts": null,
    "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
    "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
    "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756315645,
      "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
      "id": 136542130,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203006359/image_2203006359.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
      "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570"
    }
  },
  {
    "ts": null,
    "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
    "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
    "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303500,
      "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
      "id": 136539572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
      "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3"
    }
  },
  {
    "ts": null,
    "headline": "How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy",
    "summary": "On August 25, 2025, Acadia Pharmaceuticals announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer, bringing her extensive leadership experience from Teva Pharmaceuticals and Bristol Myers Squibb. Katcheves’s proven record in advancing major pharmaceutical transactions and expanding innovative pipelines highlights Acadia’s intent to strengthen its growth and business development capabilities. We'll explore how Katcheves’s...",
    "url": "https://finnhub.io/api/news?id=f9ea633097bf4687a018afc06b91037e9e740ff0e1696104363f0fa2ee51e4d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756289949,
      "headline": "How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy",
      "id": 136536715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "On August 25, 2025, Acadia Pharmaceuticals announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer, bringing her extensive leadership experience from Teva Pharmaceuticals and Bristol Myers Squibb. Katcheves’s proven record in advancing major pharmaceutical transactions and expanding innovative pipelines highlights Acadia’s intent to strengthen its growth and business development capabilities. We'll explore how Katcheves’s...",
      "url": "https://finnhub.io/api/news?id=f9ea633097bf4687a018afc06b91037e9e740ff0e1696104363f0fa2ee51e4d4"
    }
  },
  {
    "ts": null,
    "headline": "Redwire Corporation (RDW): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Redwire Corporation on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on RDW. Redwire Corporation’s share was trading at $8.70 as of August 20th. Redwire is emerging as a critical player in the space economy, evolving from a niche space infrastructure provider into a multidisciplinary aerospace and […]",
    "url": "https://finnhub.io/api/news?id=473b80ecc513e84ec3c0153c0ae4d203317b2e50b300d6dc691e0d4b6e7fa27b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285734,
      "headline": "Redwire Corporation (RDW): A Bull Case Theory",
      "id": 136536304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Redwire Corporation on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on RDW. Redwire Corporation’s share was trading at $8.70 as of August 20th. Redwire is emerging as a critical player in the space economy, evolving from a niche space infrastructure provider into a multidisciplinary aerospace and […]",
      "url": "https://finnhub.io/api/news?id=473b80ecc513e84ec3c0153c0ae4d203317b2e50b300d6dc691e0d4b6e7fa27b"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.",
    "url": "https://finnhub.io/api/news?id=df5edad64cbf61db8a69dbcca14e632f0a6483acf5cb9cc9780e835948b9d781",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756265540,
      "headline": "Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)",
      "id": 136536717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.",
      "url": "https://finnhub.io/api/news?id=df5edad64cbf61db8a69dbcca14e632f0a6483acf5cb9cc9780e835948b9d781"
    }
  }
]